January 2025 marks five years since the beginning of the COVID-19 pandemic that resulted in 1,216,305 American deaths and ...

Even though people may be getting better at fighting the illness, COVID-19 is still dangerous to vulnerable groups. And so ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Robert F. Kennedy Jr., the HHS secretary nominee, has said he is not antivaccine, but he has a track record of casting doubt ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

Even when the bogus papers are spotted – usually by amateur sleuths on their own time – academic journals are often slow to retract the papers, allowing the articles to taint what many consider ...

在这一部分中，Verbeke及其团队回顾了mRNA疫苗发展的历史，探讨了mRNA作为治疗方法的发现与生产，寻找安全有效的传递载体，以及其临床进展。他们指出，优质mRNA疫苗可有效诱导由先天与适应性免疫系统共同激活的免疫反应。

I don’t think proteomics will win over genomics," Sanghera said. "They go hand-in-glove. We’ve been overly focused [on genomics], and now we’re going to see an emergence of proteomics. And when the ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose ...